Anti-Helicobacter pylori activity and structure-activity relationship study of 2-alkylthio-5-(nitroaryl)-1,3,4-thiadiazole derivatives

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 3, 2013, Pages 281-287

  Asadipour, Ali ^a   Edraki, Najmeh ^b,c   Nakhjiri, Maryam ^b   Yahya Meymandi, Azadeh ^b   Alipour, Eskandar ^d   Saniee, Parastoo ^e   Siavoshi, Farideh ^e   Shafee, Abbas ^a   Foroumadi, Alireza ^a,b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e UNIVERSITY OF TEHRAN   (Iran)

Author keywords

1,3,4 thiadiazole; Anti helicobacter pylori activity; Nitroheterocycle

Indexed keywords

2 ALKYLTHIO 5 (NITROARYL) 1,3,4 THIADIAZOLE; ANTIINFECTIVE AGENT; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DISK DIFFUSION; GROWTH INHIBITION; HELICOBACTER PYLORI; INFRARED SPECTROSCOPY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 84883788844     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gisbert JP, Pajares R and Pajares JM. Evolution of Helicobacter pylori therapy from ameta-analytical perspective. Helicobacter (2007) 12 Suppl: 50-58.
2. Gisbert JP and Pajares JM. Treatment of Helicobacter pylori infection: The past and the future. Eur. J. Intern. Med. (2010) 21: 357-359.
3. Bayerdorer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S and Stolte M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet (1995) 345: 1591-1594.
4. Logan RP. Helicobacter pylori and gastric cancer. Lancet (1994). 344: 1078-1079.
5. Petersen AM and Krogfelt KA. Helicobacter pylori: an invading microorganism? A review. FEMS Immunol. Med. Microbiol. (2003) 36: 117-126.
6. Candelli M; Nista EC; Carloni E; Pignataro G; Zocco MA; Cazzato A; Di Campli C; Fini L; Gasbarrini G and Gasbarrini A. Treatment of H. pylori infection: a review. Curr. Med. Chem. (2005) 12: 375-384.
7. Sepulveda AR. Helicobacter pylori and gastric malignancie. Helicobacter (2002) 7: 37-42.
8. Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ and Frenck RW, Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J. Clin. Microbiol. (2004) 42: 4832-4834.
9. Ndip RN, Malange Tarkang AE, Mbullah SM, Luma HN, Malongue A, Ndip LM, Nyongbela K, Wirmum C and Efange SM. In-vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. J. Ethnopharmacol. (2007) 114: 452-457.
10. Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi F, Mehrabani M, Hosseinzadeh H, Foroumadi P, Safavi M, Khanavi M, Akbarzadeh T, Shafee A and Foroumadi A. In-vitro antibacterial activity of some Iranian medicinal plant extracts against Helicobacter pylori. Natural Product Research (2011) 25: 1059-1066.
11. Galan MV, Kishan AA and Silverman AL. Oral broccoli sprouts for the treatment of Helicobacter pylori infection: a preliminary report. Dig. Dis. Sci. (2004) 49: 1088-1090.
12. Nariman F, Eftekhar F, Habibi Z and Falsaf T. Anti-Helicobacter pylori activities of six Iranian plants. Helicobacter (2004) 9: 146-151.
13. Funatogawa K, Hayashi S, Shimomura H, Yoshida T, Hatano T, Ito H and Hirai Y. Antibacterial activity of hydrolyzable tannins derived from medicinal plants against Helicobacter pylori. Microbiol. Immunol. (2004) 48: 251-261.
14. Chimenti F, Bizzarri B, Bolasco A, Secci D, Chimenti P, Granese A, Carradori S, Rivanera D, Zicari A, Scaltrito MM and Sisto F. Synthesis, selective anti-Helicobacter pylori activity, and cytotoxicity of novel N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides. Bioorg. Med. Chem. Lett. (2010) 20: 4922-4926.
15. Phillips OA and Matowe WC. Antibacterial agents (oxazolidinones, quinolones, macrolides and new agents): patent highlights June to December 2000. Curr. Opin. Investig. Drugs (2001) 2: 745-751.
16. Nair MD and Negarajan K. Nitroimidazoles as Chemotherapeutic Agents. Prog. Drug. Res. (1983) 27: 163-257.
17. Williamson JS. Helicobacter pylori: Current chemotherapy and new targets for drug design. Curr. Pharm. Des. (2001) 7: 355-392.
18. Edwards DI. Nitroimidazoles drugs. Action and resistance mechanisms. I. Mechanism of action. J. Antibiot. Chemother. (1993) 31: 9-20.
19. Amir M, Kumar H and Javed SA. Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid. Eur. J. Med. Chem. (2008) 43: 2056-2066.
20. Foroumadi A, Sakhteman A, Sharifzadeh Z Mohammadhosseini N, Hemmatinejad B, Moshaf MH, Vosooghi M, Amini M and Shafee A. Synthesis, antituberculosis activity and QSAR study of some novel 2-(nitroaryl)-5-(nitrobenzylsulfnyl and sulfonyl)-1,3,4-thiadiazoloe derivatives. Daru (2007) 15: 218-226.
21. Padmavathi V, Reddy GS, Padmaja A, Kondaiah P and Shazia A, Synthesis, Antimicrobial and Cytotoxic Activities of 1,3,4-Oxadiazoles, 1,3,4-Thiadiazoles and 1,2,4-Triazoles. Eur. J. Med. Chem. (2009) 44: 2106-2112.
22. Moshaf MH, Sorkhi M, Emami S, Nakhjiri M, Yahya-Meymandi A, Negahbani AS, Siavoshi F, Omrani M, Alipour E, Vosooghi M, Shafee A and Foroumadi A. 5-Nitroimidazole-based 1,3,4-Thiadiazoles: Heterocyclic Analogs of Metronidazole as Anti-Helicobacter pylori Agents. Arch. Pharm. Chem. Life Sci. (2011) 11: 178-183.
23. Fallah Tafti A, Akbarzadeh T, Saniee P, Siavoshi F, Shafee A and Foroumadi A. Synthesis and anti-Helicobacter pylori activity of (4-nitro-1-imidazolylmethyl)-1,2,4-triazoles, 1,3,4-thiadiazoles, and 1,3,4-oxadiazoles. Turk. J. Chem. (2011) 35: 307-316.
24. Mohammadhosseini N, Asadpour A, Letafati B, Vosooghi M, Siavoshi F, Shafee A and Foroumadi A. Synthesis and in-vitro anti-Helicobacter pylori activity of 2-(substituted benzylthio)-5-(5-nitro-2- furyl)-1, 3, 4-thiadiazole derivatives. Turk. J. Chem. (2009) 33: 471-478.
25. Tahghighi A, Rezazade Marznaki F, Kobarfard F, Dastmalchi S, Shahbazi Mojarrad J, Razmi S, Kabudanian Ardestani S, Emami S, Shafee A and Foroumadi A. Synthesis and antileishmanial activity of novel 5-(5-nitrofuran-2-y1)-1,3,4-thiadiazoles with piperazinyl-linked benzamidine substituents. Eur. J. Med. Chem. (2011) 46: 2602-2608.
26. Alipour E, Emami S, Yahya-Meymandi A, Nakhjiri M, Johari F, Ardestani SK, Poorrajab F, Hosseini M, Shafee A and Foroumadi A. Synthesis and antileishmanial activity of 5-(5-nitroaryl)-2-substituted-thio-1,3,4-thiadiazoles. J. Enzyme Inhib. Med. Chem. (2011) 26: 123-128.